CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing…
15 analysts rate CGON Buy on consensus.
Consensus price target: $91.08 (+45.63% upside from $62.54)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| POST LEONARD E director | Sep 15, 2026 | Sale | 1,000 | $72.98K |
| POST LEONARD E director | Jul 15, 2026 | Sale | 1,000 | $71.17K |
| POST LEONARD E director | Jun 24, 2026 | Sale | 5,000 | $350K |
| POST LEONARD E director | Jun 22, 2026 | Sale | 5,000 | $325K |
| Mulay James director | Jun 15, 2026 | Sale | 1,310 | $78.76K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $4.04M | +254.7% | $-161M |
| 2024 | $1.14M | +458.33% | $-88.04M |
| 2023 | $204K | +6.81% | $-48.61M |
Stock data for CGON: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics